Influenza Rapid Diagnostic Tests
Policy discussing clinical performance, accuracy, and use of rapid antigen-based and molecular point-of-care tests for detecting influenza A and B; intended for providers and payers evaluating diagnostic testing choices and coverage.
No material clinical or coverage changes in this revision.
Coverage Criteria
Rapid antigen–based diagnostic tests for influenza are noted to have high false‑negative rates, which limits their reliability as standalone diagnostic tools. For coverage determinations, this policy therefore treats rapid antigen tests as less dependable for definitive diagnosis compared with molecular methods.
Molecular assays (for example, RT‑PCR and multiplex PCR) are reported to provide higher diagnostic accuracy across the pathogens discussed and are preferred when a more accurate result is required for clinical decision‑making.
Evaluation of patients with influenza-like illness (ILI) or suspected acute respiratory infection
Covered when the patient presents with symptoms suggestive of influenza-like illness (ILI) or an acute respiratory infection AND testing is used to identify influenza A or B or to aid differentiation of viral vs bacterial lower respiratory infection in community settings:
ALL of the following
ONE of
- Patient presents with influenza-like illness (ILI) or suspected acute respiratory infection (clinical suspicion prompting testing).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.